Palmoplantar Pustulosis Burden Exceeds Psoriasis Alone, Danish Cohort Finds

Patients with palmoplantar pustulosis carry a greater disease burden and worse quality of life than patients with psoriasis alone. That's the central finding of a cross-sectional study published in the Journal of the American Academy of Dermatology, Volume 95, Issue 5, in November 2026.

The study ran inside the Danish Skin Cohort, a national registry-based framework that has made Denmark one of the most productive countries in Europe for quantifying skin-disease burden. Authors Sascha Dinsen Wreschner Stave, Lea Krog Nymand, David Thein, Mikkel Bak Jensen, Simon Francis Thomsen, Jacob P. Thyssen, Alexander Egeberg and Farzad Alinaghi analyzed cross-sectional cohort data comparing patients with palmoplantar pustulosis against patients with psoriasis without palmoplantar involvement.

The comparison matters clinically. Palmoplantar pustulosis — sterile pustules localized to palms and soles, frequently co-occurring with psoriasis — sits at the edge of psoriasis classification. Some registries code it under psoriasis; others treat it separately. When outcomes are pooled, the distinct burden of PPP disappears into the average.

What does this change for dermatology practice?

For clinicians, the study's framing sharpens a practical point: a patient with pustular lesions on the palms and soles is not, in burden terms, a psoriasis patient plus a footnote. The cross-sectional design captured burden and quality-of-life measures at a single time point, and the authors report the PPP group scoring worse than the psoriasis-only group on both.

That ordering — PPP above psoriasis-only on burden — is consistent with what palm-and-sole anatomy predicts. Lesions on weight-bearing and grip surfaces interfere with walking, work and daily handling tasks in ways plaque psoriasis on the trunk may not, however extensive the body-surface involvement.

The Danish Skin Cohort infrastructure gives the finding its weight. With linked national registry data and validated questionnaire follow-up, the cohort supports large-sample comparisons that single-center series cannot. Thyssen and Egeberg, both at Gentofte Hospital, University of Copenhagen, have built much of the modern Danish burden-of-skin-disease literature on this platform; Alinaghi has led its psoriasis comorbidity and quality-of-life work.

Why the distinction matters for future classification

The study lands in an ongoing debate about whether palmoplantar pustulosis should be classified as a psoriasis subtype or as a separate entity. Burden data of this kind — showing measurably worse quality of life when PPP is present — feeds that discussion with patient-reported evidence rather than histologic argument alone.

For trial design, the implication runs in the same direction. If PPP patients report heavier burden, pooling them with plaque psoriasis cohorts could underpower endpoints in subgroups that most need effective therapy, and overstate expected benefit derived from plaque-predominant data.

As the Danish Skin Cohort matures, longitudinal follow-up will show whether the burden gap the cross-sectional analysis captured at one time point persists, widens or responds to targeted therapy.